S1 Data - by Alexander Hu (14755811)

Subjects:

Time-resolved EELS spectra, as a function of decreasing water vapor pressure. by Cathal Cassidy (1758703)

<i>Ang1</i>-KO mice develop more severe colitis compared to WT mice. by Alexander Hu (14755811)

Subjects:

<i>Ang1</i>-deficient mice are associated with alterations in the gut microbiome. by Alexander Hu (14755811)

Subjects:

Experimental protocol. by Alexander Hu (14755811)

Subjects:

<i>Ang1</i>-deficient mice develop significantly fewer tumors compared to WT mice following AOM-DSS. by Alexander Hu (14755811)

Subjects:

Differential <i>Ang1</i> and <i>Ang4</i> mRNA expression following AOM-DSS exposure. by Alexander Hu (14755811)

Subjects:

Downregulation of G9a induces autophagy and decreases tumorigenicity in neuroblastoma cells. by Xiao-Xue Ke (626989)

The effect of STOX1A on cell proliferation in the neuroblastoma cell-line SH-SY5Y. by Daan van Abel (214754)

“…(C) Overexpression and knockdown of STOX1A was determined with quantitative RT-PCR showing a mean 21 fold (mean ΔΔCt 4.4) increase in mRNA expression for STOX1A in stably transfected SH-SH5Y cells compared to the controls (Left bar) and a mean 71 fold (mean ΔΔCt 6.15) decreased mRNA expression for STOX1A siRNA transfected SH-SY5Y cells compared to the scrambled controls (right bar). …”

The SW480 cells were treated with the S100A1 (blue, Lanes 2, 3 and 4). by Md. Imran Khan (4853302)

Values for the calculation of the time-dependent drug concentrations in the system based on observed data found and derived from a variety of sources. by J. Roadnight Sheehan (20141887)

THS exposure in conjunction with antioxidant treatment for 2.5 and 5 months alleviates metabolic syndrome in a dose-dependent manner. by Neema Adhami (516427)

“…<p><b>(A)</b> THS-exposed mice treated with antioxidants for 5 months have reduced visceral fat accumulation compared to THS exposed mice. …”

Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis by Laura V. Minard (349145)

“…The overall proportion of NSSPP beneficiaries dispensed a statin increased approximately 4-fold during the study period. …”

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)